BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed TTRX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:2ae80c7f32092a3e9aa6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:TTRX P2/P3 readout (est.): GX-03 in AD
DESCRIPTION:A Double-Blind\, Randomized\, Vehicle-Controlled Phase 2 Study 
 to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate
  to Severe Atopic Dermatitis (Eczema)\nNCT07355075 | PHASE2/PHASE3 | RECRU
 ITING | sponsor: Turn Therapeutics\nPrimary completion date (ESTIMATED)\; 
 top-line results usually follow later.\nTicker TTRX (confidence 0.9)\nSour
 ce: https://clinicaltrials.gov/study/NCT07355075\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07355075
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
